西非与东南亚七国HIV治疗前耐药流行率研究
该研究在布基纳法索、喀麦隆、科特迪瓦、马里、多哥、泰国和越南七国招募1153名成人ART初始治疗者,于2015年12月至2016年11月进行HIV耐药检测。总体治疗前耐药(PDR)频率为15.9%(95%CI:13.8%-18.3%),各国范围从布基纳法索9.6%至多哥24.6%,多数国家超过10%,提示需紧急采取预防耐药措施并考虑从NNRTI转向更稳健的药物类别。
要点
- 七国总体PDR频率为15.9%(95%CI:13.8%-18.3%)
- 多数国家PDR超过10%,多哥最高达24.6%
- NNRTI耐药突变流行率为12%,NRTI和PI分别为4%和3%
核心结论
- 多数国家治疗前耐药超过10%,需开展全国代表性调查确认趋势。
- 应紧急实施预防耐药措施,包括从NNRTI转向更稳健的药物类别。
研究设计与样本
- 2015年12月至2016年11月在七国主要ART诊所招募成人ART初始治疗者。
- 共招募1153名参与者,生成1020条核苷酸序列。
- 所有标本进行HIV耐药检测,使用Stanford算法解读。
主要发现
- 总体PDR频率为15.9%(95%CI:13.8%-18.3%)。
- 各国PDR频率:布基纳法索9.6%、泰国10.2%、越南14.7%、马里15.4%、科特迪瓦16.5%、喀麦隆19.3%、多哥24.6%。
- NNRTI耐药突变流行率为12%,NRTI和PI PDR流行率分别为4%和3%。
临床怎么用
- 在多数PDR超过10%的国家,应紧急考虑从NNRTI转向更稳健的药物类别。
- 需开展全国代表性调查以确认PDR趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ART in the developing world has moved to a new era with the WHO recommendation to test and immediately treat HIV-positive individuals. A high frequency of pretreatment HIV drug resistance (PDR) can compromise ART efficacy. Our study presents updated estimates of PDR in seven countries from West Africa (Burkina Faso, Cameroon, Côte d'Ivoire, Mali and Togo) and Southeast Asia (Thailand and Vietnam). METHODS: Eligible study participants were adult ART initiators, recruited from December 2015 to November 2016 in major ART clinics in each country. HIV drug resistance (HIVDR) tests were performed for all specimens and interpretation was done using the Stanford algorithm. RESULTS: Overall, 1153 participants were recruited and 1020 nt sequences were generated. PDR frequency among all initiators was 15.9% (95% CI: 13.8%-18.3%) overall, ranging from 9.6% and 10.2% in Burkina Faso and Thailand, respectively, 14.7% in Vietnam, 15.4% in Mali, 16.5% in Côte d'Ivoire and 19.3% in Cameroon, to 24.6% in Togo. The prevalence of NNRTI resistance mutations was 12%; NRTI and PI PDR prevalences were 4% and 3%, respectively. CONCLUSIONS: Our study shows that in most countries PDR exceeded 10%, warranting the conduct of nationally representative surveys to confirm this trend. In the meantime, actions to prevent drug resistance, including transition from NNRTIs to more robust drug classes should be urgently implemented.
引用
- Ngo-Giang-Huong N, Huynh THK, Dagnra AY, et al. Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries. J Antimicrob Chemother. 2019. PMID: 30418575. doi:10.1093/jac/dky443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。